These observations support the notion that CXCL10 may function as a common mediator of immune activation and tissue injury in both hepatic and systemic settings, potentially in the inflammatory and vascular interactions that connect MASLD and SAH. The gene discussed is CXCL10; the disease is metabolic dysfunction-associated steatotic liver disease.